menu
    • menu
    [{"orgOrder":0,"company":"Orbis Medicines","sponsor":"Novo Holding","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Orbis Medicines","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Orbis Medicines \/ Novo Holding","highestDevelopmentStatusID":"3","companyTruncated":"Orbis Medicines \/ Novo Holding"},{"orgOrder":0,"company":"Orbis Medicines","sponsor":"Vivtex","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"nCycles","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery Platform","graph3":"Orbis Medicines","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orbis Medicines \/ Orbis Medicines","highestDevelopmentStatusID":"3","companyTruncated":"Orbis Medicines \/ Orbis Medicines"}]

    Find Clinical Drug Pipeline Developments & Deals by Orbis Medicines

    Menu

    Orbis Medicines

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orbis Medicines

                            Denmark arrow
                            ESCRS
                            Not Confirmed

                            Orbis Medicines

                            Denmark arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : nCycles

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery Platform

                            Recipient : Vivtex

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orbis and Vivtex Partner To Develop Oral nCycles Drugs

                            Details : The collaboration will enable Orbis to utilize Vivtex’s GI-ORIS platform for gut permeability screening to evaluate the oral bioavailability of Orbis’ portfolio of next-generation macrocycle drugs.

                            Product Name : nCycles

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 17, 2024

                            Lead Product(s) : nCycles

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery Platform

                            Recipient : Vivtex

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Orbis Medicines

                            Denmark arrow
                            ESCRS
                            Not Confirmed

                            Orbis Medicines

                            Denmark arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Novo Holding

                            Deal Size : $28.1 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Orbis Medicines Launches with €26 Million Seed Financing for Macrocycle Drugs

                            Details : The funding will support Orbis’ expansion and advancement of its next-generation macrocycle drugs, known as nCycles, designed for oral bioavailability and membrane permeability.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 29, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Novo Holding

                            Deal Size : $28.1 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth